ReviewStroke (Hoboken, N.J.)2023
Antiplatelet Resistance: A Review of Concepts, Mechanisms, and Implications for Management in Acute Ischemic Stroke and Transient Ischemic Attack.
Review in Stroke (Hoboken, N.J.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- P2YJournal of atherosclerosis and thrombosis · 2026Trial
- Platelet function in patients undergoing major non-cardiac vascular surgery (PLUGS): a prospective cohort study.Anaesthesia · 2026Observational
- Cyclomulberrin fromRSC advances · 2026Article
- Assessing Functional Recovery in Ischemic Stroke: An Observational Study of Dual vs. Single Antiplatelet Therapy in Indian Patients.Health science reports · 2026Article
- Safety of dual antiplatelet therapy using aspirin and low-dose Prasugrel with platelet reactivity testing in flow diverter treatment of intracranial aneurysms.Interventional neuroradiology : journal of peritherapeutic neuroradiology, surgical procedures and related neurosciences · 2026Article
- Overcoming Clopidogrel Resistance in Carotid Artery Stenting: Experience with Ticagrelor and Ticlopidine.Clinics and practice · 2026Article
- Efficacy and safety of clopidogrel and aspirin in patients with chronic coronary syndrome: a systematic review and meta-analysis.Frontiers in cardiovascular medicine · 2026Review
- Ticagrelor Versus Clopidogrel or Aspirin in Secondary Stroke Prevention: Systematic Review and Meta-Analysis of Randomized Controlled Trials.Stroke research and treatment · 2026Review
- Silent Dangers in Elderly Pharmacotherapy: The Interplay of Polypharmacy, Multimorbidity, and Drug Interactions.Journal of evaluation in clinical practice · 2025Review
- A Case of Extended Duration Triple Antithrombotic Therapy in a Patient With an Intracranial Stent and Atrial Fibrillation.The Neurohospitalist · 2025Article
- PICASSO (Proximal Internal Carotid Artery Acute Stroke Secondary to Tandem Lesion or Local Occlusion) Thrombectomy Randomized Trial: Study Protocol and Rationale.Stroke (Hoboken, N.J.) · 2025Article
- Clinical implications of platelet reactivity after antiplatelet initiation in patients with acute ischaemic stroke.BMC neurology · 2025Observational
- Article
- Dihydrogeodin fromMarine drugs · 2025Article
- Switching antiplatelet therapy based on P2Y12 reaction unit monitoring for recurrent acute thrombosis due to prasugrel resistance: A case report.Journal of cardiology cases · 2025Article
- Serial Examination of Platelet Function Tests Might Predict Prognosis of Patients with Acute Ischemic Stroke-A Cohort Study.Diagnostics (Basel, Switzerland) · 2024Article
- Outcome of tailored antiplatelet therapy in carotid stenting: a retrospective comparative study.CVIR endovascular · 2024Article
- Molecular genomic and epigenomic characteristics related to aspirin and clopidogrel resistance.BMC medical genomics · 2024Article
- Basilar Artery Occlusion Thrombectomy Technique: An International Survey of Practice Patterns.Stroke (Hoboken, N.J.) · 2023Article
- Endovascular Therapy for Acute Stroke: New Evidence and Indications.Journal of neuroendovascular therapy · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute ischemic stroke is a leading cause of death and major disability worldwide. Approximately 50% of ischemic strokes are caused by atherothrombotic occlusion of the cerebral arteries, and antiplatelets are the mainstay of secondary stroke preventative treatment. Aspirin is beneficial if given early, and short-term treatment using aspirin and clopidogrel is increasingly used for patients with intracranial atherosclerotic disease, minor stroke, and or transient ischemic attack. However, up to 50% of patients continue to have recurrent stroke and major vascular events, which may be partly attributable to resistance to aspirin and or clopidogrel. Although the precise mechanisms are unknown, clinical and genetic factors associated with bioavailability and binding to target receptors are implicated. This narrative review begins with the concept of aspirin and clopidogrel resistance in ischemic stroke and transient ischemic attack, potential mechanisms including genetic polymorphisms, and an overview of platelet function measures and limitations. We conclude by highlighting practical issues in the management of patients with aspirin andclopidogrel resistance including the emerging interest in ticagrelor, prasugrel, and cilostazol as well as directions for future trials in transient ischemic attack and acute ischemic stroke.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.